Killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 1 (KIR3DL1; CD158E1); KIR3DL2; (CD158K); KIR3DL3 (CD158Z); CD20 BriefCommunication Pages: 84 - 84
Programmed cell death 1 (PDCD1; PD-1; CD279); hepatitis A virus cellular receptor 2 (HAVCR2; TIM3) BriefCommunication Pages: 85 - 85
Eukaryotic translation initiation factor 2α kinase 3 (EIF2AK3; PERK); TAR DNA binding protein 43 (TDP-43; TARDBP) BriefCommunication Pages: 94 - 94
Clustered, regularly interspaced short palindromic repeats (CRISPR)-based genome-wide screening platform BriefCommunication Pages: 98 - 98
Orexin (hypocretin; HCRT)-based immunoassays to diagnose narcolepsy BriefCommunication Pages: 99 - 99
An algorithm to predict drug combinations to treat genetically heterogeneous tumors BriefCommunication Pages: 100 - 100
Asymmetrical Fc engineering to enhance antibody-dependent cellular cytotoxicity (ADCC) BriefCommunication Pages: 101 - 101
Pluripotent cell–derived nephron progenitor cells and self-organizing 3D structures BriefCommunication Pages: 102 - 102
Magnetic resonance spectroscopy (MRS) of hyperpolarized (2H,13C)-labeled glucose to detect tumor response to drug treatment BriefCommunication Pages: 103 - 103